These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 18650261)
1. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Buller CL; Loberg RD; Fan MH; Zhu Q; Park JL; Vesely E; Inoki K; Guan KL; Brosius FC Am J Physiol Cell Physiol; 2008 Sep; 295(3):C836-43. PubMed ID: 18650261 [TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure. Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586 [TBL] [Abstract][Full Text] [Related]
3. GLUT1 enhances mTOR activity independently of TSC2 and AMPK. Buller CL; Heilig CW; Brosius FC Am J Physiol Renal Physiol; 2011 Sep; 301(3):F588-96. PubMed ID: 21613414 [TBL] [Abstract][Full Text] [Related]
4. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Vigneron F; Dos Santos P; Lemoine S; Bonnet M; Tariosse L; Couffinhal T; Duplaà C; Jaspard-Vinassa B Cardiovasc Res; 2011 Apr; 90(1):49-56. PubMed ID: 21233250 [TBL] [Abstract][Full Text] [Related]
5. mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition. Bhaskar PT; Nogueira V; Patra KC; Jeon SM; Park Y; Robey RB; Hay N Mol Cell Biol; 2009 Sep; 29(18):5136-47. PubMed ID: 19620286 [TBL] [Abstract][Full Text] [Related]
7. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215 [TBL] [Abstract][Full Text] [Related]
10. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Inoki K; Ouyang H; Zhu T; Lindvall C; Wang Y; Zhang X; Yang Q; Bennett C; Harada Y; Stankunas K; Wang CY; He X; MacDougald OA; You M; Williams BO; Guan KL Cell; 2006 Sep; 126(5):955-68. PubMed ID: 16959574 [TBL] [Abstract][Full Text] [Related]
11. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076 [TBL] [Abstract][Full Text] [Related]
12. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463 [TBL] [Abstract][Full Text] [Related]
13. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121 [TBL] [Abstract][Full Text] [Related]
14. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Inoki K; Li Y; Xu T; Guan KL Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586 [TBL] [Abstract][Full Text] [Related]
15. Homologous posttranscriptional regulation of insulin-like growth factor-I receptor level via glycogen synthase kinase-3beta and mammalian target of rapamycin in adrenal chromaffin cells: effect on tau phosphorylation. Nemoto T; Satoh S; Maruta T; Kanai T; Yoshikawa N; Miyazaki S; Yanagita T; Wada A Neuropharmacology; 2010 Jun; 58(7):1097-108. PubMed ID: 20144629 [TBL] [Abstract][Full Text] [Related]
16. The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Jiang X; Kenerson H; Aicher L; Miyaoka R; Eary J; Bissler J; Yeung RS Am J Pathol; 2008 Jun; 172(6):1748-56. PubMed ID: 18511518 [TBL] [Abstract][Full Text] [Related]
17. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes. Miyazaki M; McCarthy JJ; Esser KA FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061 [TBL] [Abstract][Full Text] [Related]
18. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth. Gan B; Yoo Y; Guan JL J Biol Chem; 2006 Dec; 281(49):37321-9. PubMed ID: 17043358 [TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway. Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130 [TBL] [Abstract][Full Text] [Related]
20. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Zeng Z; Sarbassov dos D; Samudio IJ; Yee KW; Munsell MF; Ellen Jackson C; Giles FJ; Sabatini DM; Andreeff M; Konopleva M Blood; 2007 Apr; 109(8):3509-12. PubMed ID: 17179228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]